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Chronic hepatitis C is a major healthcare problem. The
response to antiviral therapy for patients with chronic
hepatitis C has previously been defined biochemically
and by PCR. However, changes in the hepatic venous
pressure gradient (HVPG) may be considered as an
adjunctive end point for the therapeutic evaluation of
antiviral therapy in chronic hepatitis C. It is a validated
technique which is safe, well tolerated, well established,
and reproducible. Serial HVPG measurements may be
the best way to evaluate response to therapy in chronic
hepatitis C.
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Chronic hepatitis C is a major healthcareproblem: there are some 170 millionchronic hepatitis C virus (HCV) carriers
throughout the world of whom an estimated four
million are in the USA and five million inWestern
Europe.1
HCV accounts for 20% of cases of acute hepati-
tis, 70% of cases of chronic hepatitis, 40% of cases
of end stage cirrhosis, 60% of cases of hepatocel-
lular carcinoma, and 30% of cases of liver
transplantation. In patients with chronic hepati-
tis C, one of the first findings that signal the
development of cirrhosis is a decrease in platelet
count, indicative of portal hypertension and
hypersplenism. About 20% of patients with
chronic hepatitis C develop cirrhosis in 10–20
years, and may die from liver related causes.2 3
Antiviral therapy is used to try and prevent this
progression.
The response to antiviral therapy for patients
with chronic hepatitis C was at first only defined
biochemically as a reduction in an elevated serum
alanine aminotransferase level. However, today,
detection of HCV RNA by polymerase chain reac-
tion (PCR) is the “gold standard” to monitor
treatment in HCV patients.4 5
However, the relationship between virological
response to therapy as a surrogate marker for the
arrest or delay in the progression to cirrhosis has
not been clearly established. Studies have shown
that a sustained biochemical or virological re-
sponse is associated with a significant decrease in
inflammation and more importantly in fibrosis.6–9
Furthermore, Shiffman and colleagues10 showed
that one third of patients who had no biochemical
response after interferon therapy achieved similar
improvement in hepatic histology to those pa-
tients with biochemical response.
There are also other data to support the finding
that the histological response may be partly inde-
pendent of biochemical and virological effects of
interferon monotherapy, and that continuing
treatment for long periods in biochemical non-
responders may improve both grading and
staging of liver histology. This could be related to
the antifibrogenic and anti-inflammatory effect
of interferon.7 8 10–16
“The relationship between virological
response to therapy as a surrogate marker
for the arrest or delay in the progression to
cirrhosis has not been clearly established”
However, there are several important limita-
tions and sources of bias which prevent an accu-
rate and reliable evaluation of the histological
benefit of antiviral therapy for chronic hepatitis C.
There are inconsistencies in the definition of
pathological features, processing of specimens,
sampling errors, and intra/interobserver variabil-
ity, so that changes in liver histology are not pre-
cise quantitative estimates.17 Flamm and
colleagues18 demonstrated histopathological
heterogeneity in chronic HCV infection: 34% of
patients had a different fibrosis score in each
biopsy sample. Moreover, there is no firm
evidence that fibrosis is regularly distributed
throughout all of the liver,19 20 thus the usual right
sided biopsy may not be representative of “true”
fibrosis.
Although changes in histological fibrosis can
be considered the closest to “the true end points”
of liver related morbidity and mortality, obtaining
reliable information from biopsies may be diffi-
cult and therefore it will be of fundamental
importance to look for additional parameters that
can be measured more quantitatively and accu-
rately.
Measurement of portal pressure21–23 may repre-
sent this important parameter. Portal hyper-
tension is the most common and lethal complica-
tion of chronic and progressive liver disease.
Variceal haemorrhage, ascites, systolic blood
pressure, and even portal-systemic encephalopa-
thy are part of this syndrome and prognosis is
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directly related to portal pressure elevation. Portal pressure
has been shown by several studies to be an independent prog-
nostic variable in cirrhotic patients who have not bled from
varices and also in those who have bled.24
“Portal hypertension is the most common and lethal
complication of chronic and progressive liver disease”
Once a patient develops portal hypertension this becomes the
pacemaker marking the progression of liver disease.
Portal pressure is usually measured indirectly by evaluating
wedged or occluded hepatic venous pressure.22 23 This is a well
established technique that consists of introduction of a cath-
eter into the right hepatic vein after which the catheter is
advanced until it is “wedged” or a balloon is inflated.24–26 The
occluded area is quite large and larger than the area with the
catheter wedged, and therefore the pressure obtained is the
average pressure of many hepatic sinusoids; this reduces the
possibility of sampling error due to heterogeneity in the
progression of fibrosis in different areas of the liver. The area
of the liver that is investigated with this method is much larger
than the comparatively minute area analysed by liver biopsy.
The occluded or wedged pressure is corrected by subtracting
the free hepatic venous pressure or the pressure of the inferior
vena cava, the result being the hepatic venous pressure
gradient (HVPG).
Thus changes in HVPG can be considered as an adjunctive
end point for the therapeutic evaluation of antiviral therapy
for chronic hepatitis C.21–23 27 28 This is because it is a validated
technique which is safe, well tolerated, well established, and
reproducible, there is a small standard error,24 and it is known
to be a prognostic factor for long term survival in cirrhosis.24
In all of our centres we use the balloon catheter method
which makes the technique easier to use and less subject to
technical errors.26 Its value as a prognostic marker in cirrhosis,
especially of alcoholic aetiology,29 has recently been reviewed
and established by many groups.24 There are also studies
reporting its use in chronic viral hepatitis although these are
fewer in number.21–23 30 31 In the most recent study in cirrhotic
patients with chronic viral hepatitis C, measurements of
wedge hepatic venous pressure (WHVP) accurately reflected
portal pressure in both alcoholics (90%) and HCV related liver
disease (94%)22 (that is, WHVP is as accurate a measure of
portal pressure in alcoholic cirrhosis24 29 as in HCV related cir-
rhosis). Moreover, the correlation with portal pressure was as
good in asymptomatic patients as in those with decompen-
sated cirrhosis.22
“HVPG is a dynamic test that can adequately reflect
progression of disease in the precirrhotic stage”
It is established that the gradient between wedged and free
hepatic pressure, as an expression of intrahepatic resistance,
does not exceed 5 mm Hg in the absence of significant liver
disease, whereas a gradient of more than 5 mm Hg is always
associated with significant changes on liver biopsy.30 31 HVPG is
a dynamic test that can adequately reflect progression of dis-
ease in the precirrhotic stage. Pichiotti and colleagues23 found
that there is an association between the severity of the piece-
meal necrosis and sinusoidal pressure. In one of our centres,
Van Leeuwen et al found that WHVP increased with histologi-
cal progression of chronic hepatitis, and that portal hyper-
tension was present before histologically detectable cirrhosis
developed (the increase in HVPG reflecting an increase in
intrahepatic vascular resistance).30
“Serial HVPG measurements may be the best way to
evaluate response to therapy in chronic hepatitis C”
Thus serial HVPG measurements may be the best way to
evaluate response to therapy in chronic hepatitis C, particu-
larly in later stages (III and IV) when fibrous deposition is sig-
nificant. Two studies have reported results of HVPG measure-
ments in patients with chronic hepatitis C before and after
treatment with interferon.
Garcia-Tsao and colleagues,27 in a preliminary double blind
placebo controlled trial, evaluated the effect of interferon on
HVPG in patients with chronic hepatitis C and portal
hypertension. The percentage change in HVPG was signifi-
cantly greater in the interferon treated group compared with
the placebo group (p<0.01). However, there was no correla-
tion between the decrease in HVPG and decrease in alanine
aminotransferase, and there were no data on PCR HCV-RNA.
In another paper, Valla and colleagues,28 evaluating 39 hepati-
tis C cirrhosis patients treated with interferon for 48 weeks,
measured HVPG in five and found a decrease in mean HVPG
from 13.8 (3.9) to 11.1 (3.6) mm Hg, while in five control
patients it increased from 13.2 (4.8) to 14.6 (2.6) mm Hg
without a parallel histological improvement. Although these
changes were not statistically significant, there was a trend
towards a reduction in HVPG in the treated group with a 20%
reduction in baseline HVPG. Those observations, if confirmed,
suggest that this could reflect the “antifibrotic” and conse-
quent secondary haemodynamic effect of interferon, rather
than an antiviral effect. Clearly this effect can only be
evaluated using HVPG measurements.
A further advantage of measuring HVPG is that it can be
performed together with a transjugular liver biopsy24 25 32 33
which would give concomitant histological information. The
risks related to the procedure are no higher than the percuta-
neous route in patients of similar risk for biopsy and it is safer
in high risk patients such as cirrhotics with small livers, or
moderate ascites, haemodialysed patients, or haemophiliacs.
With the newer needles, adequate liver samples are obtained
even when the liver is cirrhotic. The technical success rate in
our centres is more than 95%, and the specimen obtained is
adequate for histology in 90% of cases.33 In precirrhotic
patients, one would reasonably expect the proportion of
adequate samples to be higher.
CONCLUSION
Because there is little variability in themeasurement of HVPG,
a numerical progression represents true worsening of the dis-
ease process, and if there is cirrhosis it also provides reliable
prognostic information for survival.29 34 Thus measurement of
HVPG could be considered as a dynamic marker of disease
progression in patients with HCV and an end point in anti-
viral therapy, irrespective of antiviral response. The optimal
first groups to study would be those with fibrosis in the
pretreatment biopsy as well as compensated cirrhotics who
are given antiviral therapy. Further studies should assess the
best timing of this measurement, and verify its prognostic
utility in monitoring response to antiviral therapy compared
with the current “surrogate”markers as well as new ones such
as serum markers of fibrosis.
“Measurement of HVPG could be considered as a
dynamic marker of disease progression in patients with
HCV and an end point in antiviral therapy, irrespective
of antiviral response”
In the future it is likely that a panel of fibrosis markers will
be used, reflecting both collagen deposition and breakdown.
These in themselves will need to be correlated with portal
pressure elevation as well as suitable histological material
stained for collagen. Portal pressure measurement will be the
important link prognostically between histology and serum
markers of fibrosis.
In order to test this, therapeutic trials should evaluate
HVPG combined with transjugular liver biopsy before and
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after treatment. This combined procedure is easy to perform in
practice.32 In patients who develop HVPG >10 mm Hg,
complications of portal hypertension are known to
develop24 34 and this could be an end point in studies. In
patients with normal HVPG, maintaining a normal pressure
should be a sign of good prognosis. In virological non-
responders it is not known whether a liver biopsy after treat-
ment is appropriate to evaluate therapeutic benefit following
antiviral therapy, and in cirrhotics it is not clear what should
be measured to assess long term response. In these two
groups, measurement of HVPG could be particularly useful.
Thus HVPG could be a universally applied measurement of
progression with and without antiviral therapy, irrespective of
virological response in patients with chronic hepatitis C.
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